Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

AI fundraises, tech partnerships and M&A deals, including DispatchHealth and Medically Home's tie-up, and plans for a ...

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to create new guidance around expensive drugs, as compounded GLP-1s are set to be ...

4.6-star analyst Allen Lutz said that tirzepatide likely won’t bring in much money for Hims, especially since Eli Lilly sells it for $500 per month on its own platform, while Hims lists it at a ...